Production and actions of the anandamide metabolite prostamide E2 in the renal medulla

J Pharmacol Exp Ther. 2012 Sep;342(3):770-9. doi: 10.1124/jpet.112.196451. Epub 2012 Jun 8.

Abstract

Medullipin has been proposed to be an antihypertensive lipid hormone released from the renal medulla in response to increased arterial pressure and renal medullary blood flow. Because anandamide (AEA) possesses characteristics of this purported hormone, the present study tested the hypothesis that AEA or one of its metabolites represents medullipin. AEA was demonstrated to be enriched in the kidney medulla compared with cortex. Western blotting and enzymatic analyses of renal cortical and medullary microsomes revealed opposite patterns of enrichment of two AEA-metabolizing enzymes, with fatty acid amide hydrolase higher in the renal cortex and cyclooxygenase-2 (COX-2) higher in the renal medulla. In COX-2 reactions with renal medullary microsomes, prostamide E2, the ethanolamide of prostaglandin E₂, was the major product detected. Intramedullarily infused AEA dose-dependently increased urine volume and sodium and potassium excretion (15-60 nmol/kg/min) but had little effect on mean arterial pressure (MAP). The renal excretory effects of AEA were blocked by intravenous infusion of celecoxib (0.1 μg/kg/min), a selective COX-2 inhibitor, suggesting the involvement of a prostamide intermediate. Plasma kinetic analysis revealed longer elimination half-lives for AEA and prostamide E2 compared with prostaglandin E₂. Intravenous prostamide E2 reduced MAP and increased renal blood flow (RBF), actions opposite to those of angiotensin II. Coinfusion of prostamide E2 inhibited angiotensin II effects on MAP and RBF. These results suggest that AEA and/or its prostamide metabolites in the renal medulla may represent medullipin and function as a regulator of body fluid and MAP.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism
  • Animals
  • Arachidonic Acids / metabolism*
  • Arachidonic Acids / pharmacology
  • Arterial Pressure / drug effects
  • Celecoxib
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Dinoprostone / analogs & derivatives*
  • Dinoprostone / biosynthesis
  • Dinoprostone / metabolism
  • Endocannabinoids / metabolism*
  • Endocannabinoids / pharmacology
  • Glycerides / pharmacology
  • Kidney Cortex / blood supply
  • Kidney Cortex / drug effects
  • Kidney Cortex / enzymology
  • Kidney Cortex / metabolism
  • Kidney Medulla / blood supply
  • Kidney Medulla / drug effects
  • Kidney Medulla / enzymology*
  • Kidney Medulla / metabolism*
  • Kinetics
  • Lipids / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Microsomes / drug effects
  • Microsomes / metabolism
  • Polyunsaturated Alkamides / metabolism*
  • Potassium / metabolism
  • Pyrazoles / pharmacology
  • Renal Circulation / drug effects
  • Sodium / metabolism
  • Sulfonamides / pharmacology

Substances

  • Arachidonic Acids
  • Cyclooxygenase 2 Inhibitors
  • Endocannabinoids
  • Glycerides
  • Lipids
  • Polyunsaturated Alkamides
  • Pyrazoles
  • Sulfonamides
  • medullipin I
  • prostaglandin E2 ethanolamide
  • Angiotensin II
  • glyceryl 2-arachidonate
  • Sodium
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Celecoxib
  • Dinoprostone
  • Potassium
  • anandamide